| [1] | 方文涛,傅剑华,沈毅,等. 胸腺肿瘤的诊疗:基于中国胸腺肿瘤协作组多中心回顾性研究的共识[J].中国肺癌杂志,2016,19(7):414-417. | 
																													
																						| [2] | Carter B W, Marom E M, Detterbeck F C. Approaching the patient with an anterior mediastinal mass: a guide for clinicians[J]. J Thorac Oncol, 2014, 9(9 Suppl 2):S102-S109. | 
																													
																						| [3] | Travis W D, Brambilla E, Burke A P, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart[J]. J Thorac Oncol,2015,10(9):1240-1242. | 
																													
																						| [4] | 方三高,李晟磊,陈岗. 2015年WHO肺、胸膜、胸腺及心脏肿瘤分类(胸腺)解读[J].重庆医学,2015,(36):5041-5053. | 
																													
																						| [5] | Wright C D, Wain J C, Wong D R, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size[J]. J Thorac Cardiovasc Surg, 2005,130(5):1413-1421. | 
																													
																						| [6] | Kim D J, Yang W I, Choi S S, et al. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review[J]. Chest, 2005,127(3):755-761. | 
																													
																						| [7] | Weis C A, Yao X, Dang Y, et al. The impact of thymoma histotype on prognosis in a worldwide database[J]. J Thorac Oncol, 2015,10(2):367-372. | 
																													
																						| [8] | Hu B, Yang X R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014,20(23):6212-6222. | 
																													
																						| [9] | Ma M, Yu N, Wu B. High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma[J]. Cancer Manag Res, 2019,11:3973-3979. | 
																													
																						| [10] | Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management[J]. J Thorac Oncol, 2009,4(1):119-126. | 
																													
																						| [11] | Kono S A, Heasley L E, Doebele R C, et al. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer[J]. Curr Cancer Drug Targets, 2012,12(2):107-123. | 
																													
																						| [12] | Spiegel A, Brooks M W, Houshyar S, et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells[J]. Cancer Discov, 2016,6(6):630-649. | 
																													
																						| [13] | Kemal Y, Yucel I, Ekiz K, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis[J]. Asian Pac J Cancer Prev, 2014,15(6):2651-2654. | 
																													
																						| [14] | Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies[J]. Mol Cancer, 2017,16(1):137. | 
																													
																						| [15] | Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer[J]. Br J Cancer, 2013,109(2):416-421. | 
																													
																						| [16] | Deng J, Zhang P, Sun Y, et al. Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis[J]. J Thorac Dis, 2018,10(3):1522-1531. | 
																													
																						| [17] | Krenn-Pilko S, Langsenlehner U, Thurner E M, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients[J]. Br J Cancer, 2014,110(10):2524-2530. | 
																													
																						| [18] | Feng J F, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus[J]. Medicine (Baltimore), 2017,96(4):e5886. | 
																													
																						| [19] | Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma[J]. Ann Surg, 2019 Aug DOI: 10.1097/SLA.0000000000003370 .[Epub ahead of print]. |